CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Novartis AG (NVS) / pelabresib
Forward catalyst · NVS

pelabresib

Sponsor Novartis AG · listed as NVS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

pelabresib is a drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2, 2027 (day precision, medium confidence), tied to trial NCT06401356. That trial is in Phase 3 and currently recruiting, studying Hematologic Malignancy.

Next catalyst

Event typeREADOUT
Expected date2027-06-02
As disclosedJun 2, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06401356
PhasePHASE3
StatusRECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Hematologic Malignancy; Solid Tumor; Advanced Malignancies
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More NVS catalysts

Related catalysts and sponsor